Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

被引：201

作者：

Jackman, David M. ^{[1
]}

Holmes, Alison J.

Lindeman, Neal

Wen, Patrick Y.

Kesari, Santosh

Borras, Ana M.

Bailey, Christopher

de Jong, Francisca

Jaenne, Pasi A.

Johnson, Bruce E.

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Boston, MA USA

[4] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA

[5] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA

[6] Dana Farber Canc Inst, Transplant Res Lab, Boston, MA 02115 USA

[7] AstraZeneca, Dept Drug Metab & Pharmacokinet, Macclesfield, Cheshire, England

[8] Analyt Medinet BV, Breda, Netherlands

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 27期

关键词：

D O I：

10.1200/JCO.2006.06.6126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：4517 / 4520

页数：4

共 10 条

[1] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[2] A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening [J].

Jänne, PA ;

Borras, AM ;

Kuang, YN ;

Rogers, AM ;

Joshi, VA ;

Liyanage, H ;

Lindeman, N ;

Lee, JC ;

Halmos, B ;

Maher, EA ;

Distel, RJ ;

Meyerson, M ;

Johnson, BE .

CLINICAL CANCER RESEARCH, 2006, 12 (03) :751-758

[3] A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials [J].

Jones, HK ;

Stafford, LE ;

Swaisland, HC ;

Payne, R .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 29 (1-2) :221-228

[4] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

[5] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[6] Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations [J].

Mukohara, T ;

Engelman, JA ;

Hanna, NH ;

Yeap, BY ;

Kobayashi, S ;

Lindeman, N ;

Halmos, B ;

Pearlberg, J ;

Tsuchihashi, Z ;

Cantley, LC ;

Tenen, DG ;

Johnson, BE ;

Jänne, PA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (16) :1185-1194

[7] Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors [J].

Nakagawa, K ;

Tamura, T ;

Negoro, S ;

Kudoh, S ;

Yamamoto, N ;

Takeda, K ;

Swaisland, H ;

Nakatani, I ;

Hirose, M ;

Dong, RP ;

Fukuoka, M .

ANNALS OF ONCOLOGY, 2003, 14 (06) :922-930

[8] High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib [J].

Omuro, AMP ;

Kris, MG ;

Miller, VA ;

Franceschi, E ;

Shah, N ;

Milton, DT ;

Abrey, LE .

CANCER, 2005, 103 (11) :2344-2348

[9] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[10] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [J].

Pao, W ;

Miller, VA ;

Politi, KA ;

Riely, GJ ;

Somwar, R ;

Zakowski, MF ;

Kris, MG ;

Varmus, H .

PLOS MEDICINE, 2005, 2 (03) :225-235

← 1 →